The net sales for 2023 were 217 108 euros. The net sales of Onkoloogiliste Uuringute Keskus OÜ have increased compared to 2022. The profit margin for 2023 is 32,75 %. It has decreased compared to 2022.
The company's activity is research and experimental development on biotechnology.
Plus package
39 € / kuus 47,58 € / kuus w/VATIs the company creditworthy?
Annual Report
Original PDF Annual Reports from Commercial Register (in Estonian).
Aadressid
- Physical address
- Lääne maakond, Vormsi vald, Förby küla, Jakas-Hannase, 91305
Contact data
Phone
E-mail address
Shareholders, supervisory board and other persons
Who are shareholders, beneficial owners and other connected persons?
As a user of the Credit Reports Plus package you can also see company's shareholders, beneficial owners, founders, supervisory board members and other related parties.
Financial information
| 2023 | 2022 | 2021 | |||
|---|---|---|---|---|---|
| Net sales | 217 108 | 137,15% | 91 550 | 8 619,05% | 1 050 |
| Net profit (loss) | 71 104 | 5,32% | 67 514 | 6 329,90% | 1 050 |
What are the company's liabilities, current assets, equity and balance volume?
With the Credit Reports Plus package you will also see additional economic indicators - short-term liabilities, current assets, equity and balance volume (information is available with regard to companies with annual revenue of 50,000 euro and more).
Payment remarks
Has the company had any other payment remarks?
As a user of the Credit Reports Plus package you will see any publicly available demands of bailiffs along with payment orders and proposals issued by courts of law.
Has the company had any debt collection cases within last 24 months?
As a user of the Credit Reports Plus package you will get access to detailed information on the debt collection proceedings that covers most of the Estonian debt collection market.